Previous 10 | Next 10 |
2023-03-24 07:54:10 ET Stuart Peltz, Chief Executive of rare-disease-focused biotech PTC Therapeutics ( NASDAQ: PTCT ), announced Friday that he is leaving the company after 25 years of service, handing the reins to current Chief Operating Officer Matthew Klein with immediate ...
Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics PR Newswire - Chief Operating Officer Matthew Klein , M.D., M.S., F.A.C.S. to become Chief Executive Officer and join the Board of Directors – - Conferenc...
2023-03-17 15:00:22 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calenda...
Reata Pharmaceuticals is up 183% in Wednesday afternoon terading after the US FDA on Tuesday approved the company's Friedreich's ataxia drug Skyclarys (omaveloxolone). The treatment comes with an annual list price of $330K. Skyclarys is the first drug approved for the rare mo...
PTC Therapeutics, Inc. (PTCT) Q4 2022 Earnings Conference Call February 21, 2023, 04:30 PM ET Company Participants Kylie O'Keefe - Chief Commercial Officer Stuart Peltz - Chief Executive Officer Matthew Klein - Chief Operating Officer Eric Pauwels - Chief Business ...
PTC Therapeutics press release ( NASDAQ: PTCT ): Q4 GAAP EPS of -$2.35 misses by $0.78 . Revenue of $167.41M (+1.3% Y/Y) misses by $15.66M . PTC Reaffirms Full Year 2023 Financial Guidance: PTC anticipates total revenues for the full year 2023 to be between $94...
PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results PR Newswire – 2022 total revenue of $699 million , representing 30% year-over-year growth, or $740 million and 37% growth at CER* – ...
PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Financial Results PR Newswire SOUTH PLAINFIELD, N.J. , Feb. 7, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast co...
Summary Biogen's business focuses on developing and commercializing drugs aimed at treating patients living with neurological and neurodegenerative diseases. The company's total revenue was $2,508.5 million in the third quarter of 2022, down 9.7% from the previous year. The decline ...
PTC Therapeutics Receives 2023 EURORDIS Black Pearl Company Award for Innovation PR Newswire - This award recognizes PTC's 25-year legacy in discovering and delivering novel therapies that address the underlying cause of rare diseases - SOUTH PLAINFIELD, N.J. , Feb...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....